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1. Introduction 
1.1 Introduction to the immune system and flow cytometry 
The immune system is a collection of dynamic cells that work together and interact to 
perform a variety of bodily functions. The immune system is involved in many disease 
states and changes to the immune system can be very impactful in progression or 
amelioration of a disease. The ability to monitor immune responses during disease 
progression and resolution can help to elucidate the underlying mechanisms of immune-
mediated diseases  
Flow cytometry is a method of monitoring immune responses using antibodies labeled with 
fluorochromes either directly or indirectly through a fluoresceinated secondary reagent. 
Antibodies are proteins that can bind to a particular epitope with very high affinity. To 
monitor immune responses via flow cytometry, immune cells must be isolated and 
incubated with antibodies to markers of choice. During co-incubation, antibodies randomly 
encounter cells in suspension and bind to the epitopes for which they are specific for. 
Following co-incubation, excess antibody is washed off and the cell suspension can either be 
passed through a flow cytometer immediately or the cell suspension can be fixed and 
passed through a flow cytometer at a later time. The resulting data are then analyzed and 
interpreted.  
1.2 Introduction to applications of flow cytometry in graft-versus-host disease 
Graft-versus-host disease (GVHD) is an immune mediated disease that results following 
bone marrow transplant. GVHD is caused by donor T cells that react to alloantigens 
expressed on host tissues. GVHD pathology is generally confined to the epithelia of the skin, 
liver, and intestinal tract. Following transplantation, T cell responses go through several 
phases with each phase characterized by various T cell activities. Flow cytometry provides a 
powerful tool to determine the disease state at any given time, characterize T cell responses, 
and examine the effectiveness of therapeutic intervention. 
In this chapter, we will discuss the application of flow cytometry to characterizing T cell 
responses during GVHD. We will discuss isolating T cells from relevant immune 
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compartments, applying flow cytometry to identifying disease states over time, defining the 
roles of T cell subsets during GVHD, identifying the effectiveness of specific T cell depletion 
in vivo during GVHD, and the use of bioluminescent imaging to integrate flow cytometric 
data with T cell trafficking properties.  
To monitor T cell responses during GVHD, T cells can be isolated from several locations. In 
this section of the chapter, we will describe methods for isolating and purifying T cell 
subsets from the intestinal tract, peripheral blood, mesenteric lymph node, and spleen. By 
examining these specific locations, researchers can gain insight into pathogenic T cell 
development and maintenance. We will provide data regarding T cell yield and expected 
ratios of various T cell subsets in each location.  
Flow cytometry can be a valuable asset in identifying disease progression. Flow cytometry 
allows for both cell surface and intracellular identification of T cells. This section of the 
chapter will focus on how to identify disease states during GVHD based on cell surface 
staining as well as identify intracellular cytokine production characteristic of pathogenic T 
cells. We will discuss typical surface staining of T cells during various phases of GVHD.  
The roles of T cell subsets in GVHD can be explored using data that characterizes T cell 
responses during GVHD. In this section of the chapter, we will discuss how flow cytometric 
analysis can be used to generate hypotheses about the roles of T cell subsets during GVHD. 
We will instruct the reader how to analyze flow cytometry data, draw subsequent 
conclusions, and generate hypotheses to confirm their conclusions. We will provide 
examples of this practice in the context of GVHD. 
The final section of this chapter will focus on using flow cytometry to determine the 
effectiveness of therapeutic interventions. Our lab has used immunotoxins and depleting 
antibodies as potential therapies for GVHD. Flow cytometry plays a large role in 
determining the mechanism of action of our therapies as well as determining if the therapy 
was successful. In this section, we will include data showing how flow cytometry can be 
used to determine the effectiveness of immunotherapies. 
2. Graft-versus-host disease  
2.1 Introduction to bone marrow transplantation 
Bone marrow transplantation represents a curative therapy for a variety of hematopoietic 
deficiencies including blood cancers. Because of the potentially fatal side effects, transplants 
are often only used when standard therapies are ineffective. Immediately prior to the 
transplant, the host is given a conditioning regimen of radiation and/or chemotherapy to 
suppress or ablate the host immune system. In doing so, the host is cured of their blood 
disorder; however, they are also severely immunocompromised and will not survive 
without a bone marrow transplant to restore immune function. Donor bone marrow can be 
isolated by injecting a syringe into a marrow containing bone and extracting marrow. This is 
a very laborious and painful process for the donor. Alternatively, a less invasive method of 
extracting hematopoietic stem cells involves treating the donor with granulocyte colony-
stimulating factor (G-CSF) and pheresing stem cells out of the blood. Treatment with G-CSF 
mobilizes stem cells from the bone marrow into circulation, and stem cells can then be 
isolated from peripheral blood. Donor stem cells are isolated and injected into the 
immunosuppressed host.  
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2.2 Graft-versus-host disease 
Acute Graft-versus-host disease is the most common detrimental outcome following bone 
marrow or hematopoietic stem cell transplants. In 1966, Billingham described three criteria 
for GVHD: 1) the graft must contain a sufficient number of immunologically competent cells, 
2) the host must contain important isoantigens lacking in the graft, and 3) the host must be 
incapable of mounting an immune response against the graft (Billingham, 1966). There are 
four stages of GVHD that classify the severity of the disease with stage I being the least 
severe and stage IV being the most severe. Various stages are defined by the degree of 
pathology associated with each target organ (Table 1). There are several genetic risk factors 
that can negatively impact a recipient’s probability of getting severe GVHD. These risk 
factors include, but are not limited to polymorphisms in proinflammatory cytokines such as 
TNFα and INF┛ as well as polymorphisms in anti-inflammatory cytokines such as IL-10 and 
TGF┚ (Ball & Egeler, 2008). Other risk factors include age/sex of the donor and recipient, 
donor stem cell source, and degree of HLA mismatch (Koreth & Antin, 2008). It is of great 
importance to match the donor and recipient as closely as possible. The degree of HLA 
mismatch between the donor and recipient positively correlates with the severity of GVHD 
(Park et al., 2011). GVHD is caused by mature lymphocytes that are unintentionally isolated 
during graft procurement that generate an immune response to host antigens. It is not 
uncommon for the number of mature lymphocytes to vastly outnumber the stem cells in the 
transplant inoculum (Korbling & Anderlini, 2001). T cells represent the highest single cell 
type population (Korbling & Anderlini, 2001), and are the primary mediators of GVHD. 
Mature donor antigen presenting cells (APCs) and B cells contribute to the pathogenesis of 
GVHD by priming T cells against host tissue. However, donor T cells alone are sufficient to 
cause GVHD (Shlomchik et al. 1999). Interestingly, depletion of donor CD4+ T cells is 
ineffective in reducing GVHD severity, but selective depletion of CD8+ T cells ameliorates 
GVHD severity (Nagler et al., 1998; Nimer et al., 1994). These data suggest that CD8+ T cells 
play a dominant role in promoting GVHD pathology. Patients that develop acute GVHD 
often develop chronic GVHD. Chronic GVHD is characterized by the delay in onset as well 
as the breadth of target organ involvement. Acute GVHD is diagnosed if onset occurs within 
100 days of transplant; whereas, clinical manifestations occurring after 100 days post   
Stage Skin Liver GI Tract 
0 No rash due to GVHD Normal serum 
bilirubin 
None  
I Mild maculopapular rash over 
less than 25% of the body 
Bilirubin from 2 to 
<3 mg/dl 
Diarrhea  
>500-1000 ml/day  
II Moderate maculopapular rash 
over 25%-50% of the body 
Bilirubin from 3 to 
<6 mg/dl 
Diarrhea  
>1000-1500 ml/day  
III Severe maculopapular rash 
covering greater than 50% of the 
body 
Bilirubin from 6 to 
< 15mg/dl 
Diarrhea  
>1500 ml/day  
IV Severe maculopapular rash 
covering greater than 50% of the 
body. 
Bilirubin  
> 15mg/dl 
Diarrhea  
>1500 ml/day; 
abdominal pain or ileus 
Adapted from Ball & Egeler, 2008, Bone Marrow Transplantation. 
Table 1. Description of each clinical manifestation for each target organ at each stage of GVHD 
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transplant are characterized as chronic GVHD. Target organs affected by acute GVHD are 
largely limited to the skin, liver, and gut. In addition to the skin, liver, and gut, chronic 
GVHD can affect mucous membranes, lung, and musculoskeletal system (Koreth & Antin, 
2008). 
In addition to their ability to cause GVHD, donor T cells provide protective effects to 
transplant recipients. Donor T cells promote bone marrow engraftment, immunity to 
opportunistic infections, and eliminate residual malignant cells resistant to the host 
conditioning regimen. Elimination of residual tumor cells is seen in several solid tumors 
and a variety of hematological malignancies with chronic myeloid leukemia (CML) being 
the most sensitive (Morris et al., 2006). Immunity to residual tumor cells is termed the 
graft-versus tumor (GVT) effect and immunity to hematopoietic malignancy is termed the 
graft-versus-leukemia (GVL). Transplant recipients receive a variety of immunosuppressive 
drugs, many of which target T cells. Because T cells are a major defense against viral 
infections, reactivation and primary cytomegalovirus (CMV) infections are problematic 
post transplant (Bautista et al., 2008). Intense myeloablative condition regimens destroy 
host defense responsible for maintaining CMV latency. It has been established that total 
body irradiation (TBI) causes reactivation of latent murine CMV (mCMV) infections (Kurz 
et al. 1999). Virus-specific CTLs have been generated from in vitro expanded CD8+ T cells 
and adoptively transferred into recipients (Riddel et al., 1992). Identifying a target to 
reduce GVHD and maintain immunity to a broad spectrum of pathogens would be 
advantageous to advancing our understanding of the immune system after bone marrow 
transplantation.  
In some transplants, T cells are depleted prior to transplant because the severity of GVHD 
can be predicted through analysis of the degree of mismatch between donor and host. 
Recipients of T cell depleted grafts do not develop GVHD, but they also do not benefit from 
the protective effects of T cells post transplant. It was shown that leukemic relapse and graft 
rejection were increased in patients who received T cell depleted grafts and concluded that 
global T cell depletion is not a viable treatment strategy (Horowitz et al., 1990). Therefore, 
GVHD research is focused on identifying a method to prevent GVHD while maintaining the 
beneficial T cell properties post transplant.  
2.3 Animal models of GVHD 
Animal GVHD models are often used in order to test hypotheses aimed to improve 
outcomes following bone marrow transplantation. GVHD is induced by irradiating recipient 
mice and adoptively transferring donor bone marrow cells. Unlike the clinical scenario, 
there are not enough donor T cells isolated during bone marrow procurement to induce 
GVHD, so exogenous T cells must be added to induce GVHD. The most common source of 
T cells used to induce GVHD is the spleen and/or lymph nodes. Whole splenocytes or 
various subsets of T cells can be purified and adoptively transferred with the bone marrow 
to induce GVHD.  
Advances in clinical practice have been driven by breakthroughs discovered using small 
animal models of GVHD. Rat models of GVHD are widely used and provide researchers 
with a small animal model to test hypotheses to improve outcomes following bone marrow 
transplants. Given the additional size provided in rat models compared to murine models, 
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transplant studies in which GVHD is a complication of solid organ allografts can be done 
(Wakely et al., 1990; Muramatsu et al., 2010). However, murine GVHD models remain the 
most prominent transplant models. The vast number of MHC combinations available and 
the array of transgenic mice create an ideal situation for testing hypotheses aimed to 
discover immunological mechanisms governing GVHD. Murine GVHD models can be 
divided into two main categories: MHC-matched and MHC disparate. The disease course 
following GVHD induction in MHC-disparate models is much more rapid than the disease 
course following GVHD induction in MHC-matched models, and can generally be induced 
by CD4+ or CD8+ T cells alone. Donor CD4+ and CD8+ T cells in an MHC-disparate model 
are directed against differences in major histocompatibility antigens; whereas, T cells in an 
MHC-matched model are directed against differences in the minor histocompatibility 
antigens (miHAs). miHAs are polymorphic proteins that vary between individuals. miHAs 
are sufficient to cause GVHD despite the lower frequency of donor T cells specific for miHA 
differences (Goulmy et al., 1996). An MHC-matched model that closely resembles the 
clinical scenario is the C57Bl/6 (B6) into BALB.B strain combination. Both strains are of the 
H-2b haplotype, but are disparate for multiple miHAs. This model was well characterized in 
the Korngold laboratory, and it was established that GVHD was principally caused by CD4-
dependent CD8+ T cells (Berger et al., 1994; Friedman et al., 1998). Furthermore, the 
immunodominant hierarchy has been established and it is known that the H60 miHA is 
immunodominant (Choi et al., 2001). The delayed mortality in MHC-matched models 
allows for disease progression that is more consistent with clinical disease progressions. The 
similarity of the relative roles of T cell subsets between the clinical scenario and the B6 into 
BALB.B strain combination and the delayed disease course make this model useful to study 
underlying mechanisms of GVHD.  
2.4 Effects of the conditioning regimen 
GVHD is classified into three different phases. The first phase of GVHD comes as a result of 
the conditioning regimen the recipient receives to reduce or ablate the native immune 
system. The conditioning regimen is aimed to destroy rapidly dividing cells, so in addition 
to destroying lymphocytes, the conditioning regimen also attacks epithelial cells in the skin, 
the liver, and the gut. Destruction of epithelium in these compartments is thought to cause 
release of proinflammatory cytokines including, but not limited to IL-1 and TNFα. Increased 
cytokine production causes the upregulation of costimulatory molecules, adhesion 
molecules, and MHC antigens (Chang & See, 1986; Pober et al., 1996). This process is critical 
to the activation of host antigen presenting cells (APCs). Epithelial damage in the gut is 
particularly important in the initiation of GVHD. Damage to the intestinal epithelium causes 
systemic release of LPS, which further amplifies GVHD induction (Reddy, 2003). Released 
LPS is taken up by local APCs and an immune response is mounted against LPS, which, in 
turn further exacerbates GVHD progression and pathology.  
2.5 Donor T cell activation 
GVHD pathology is mediated by donor T cells directed against major and minor 
histocompatibility antigens in the host. Donor T cell trafficking to host secondary lymphoid 
tissue immediately following hematopoietic stem cell transplantation (HSCT) is a complex 
processes that displays extreme diversity between organs. Naïve T cells cause more severe  
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GVHD than memory T cells (Dutt et al., 2007); therefore, naïve T cell trafficking is an area of 
intense research. T cell priming in intestinal inductive sites (Peyer’s patches, mesenteric 
lymph nodes) plays a major role in gut associated GVHD. In the gut, T cells enter secondary 
lymphoid tissue by T cell rolling initiated by the L-selectin (CD62L) expressed on all naïve T 
cells interacting with the peripheral node addressin (PNAd) on high endothelial venules 
(HEVs). Further tethering of the T cell to the HEV is achieved by the CCL21/CCR7 
interaction. This interaction mediates upregulation of leukocyte function-associated antigen 
type 1 (LFA-1) on T cells, which firmly bind the T cell and HEV (Johansson-Lindbom & 
Agace, 2007). Peyer’s patches and mesenteric lymph node HEVs express low levels of 
PNAd; however, mucosal addressin cell-adhesion molecule-1 (MAdCAM-1) serves as an 
additional ligand for CD62L in gut priming sites (Johansson-Lindbom & Agace, 2007). 
Another important ligand for MAdCAM-1 is the α4┚7 integrin. This integrin is expressed on 
naïve T cells and plays a critical role in directing naïve T cells to the gut, causing intestinal 
GVHD (Campbell & Butcher, 2002; Johansson-Lindbom & Agace, 2007; Mora et al., 2003; 
Stagg et al., 2002). Once in host lymphoid tissue, antigen presentation is primarily done by 
host APCs presenting self peptides. Donor derived dendritic cells can cross present host 
antigens; however, severe GVHD is dependent on host APCs presenting to alloreactive T 
cells (Shlomchik, 2007). Activated T cells leave through the efferent lymphatic system and 
return to circulation via the thorasic duct. When activated T cells return to sites of 
inflammation they migrate through blood vessel endothelium and into epithelial 
compartments. 
2.6 Effector phase of GVHD 
In the activation phase, donor T cells traffic to host secondary lymphoid tissue hours after 
transplant and expand within 2-3 days (Wysocki et al., 2005). In the lymphoid tissue, donor 
T cells are primarily primed by host antigen presenting cells (APCs) to mature into T 
helper 1 (Th1) CD4+ T cells or cytotoxic CD8+ T cells. Recently, it has been described that T 
helper 17 (Th17) cells can also mediate lethal GVHD in murine models (Carlson et al., 
2009). Th17 cells are characterized by their ability to produce the cytokine IL-17, and have 
been shown to be proinflammatory (Gran et al., 2002; Gutcher et al., 2006; Krakowski & 
Owens, 1996; Zhang et al., 2003). Th1 CD4+ T cells are characterized by their production of 
proinflammatory cytokines such as IFN┛, TNFα, and IL-2. 3-7 days post transplant, 
activated T cells traffic to and expand in GVHD target organs (Wysocki et al., 2005). The 
effector phase of GVHD consists of activated T cells migrating to epithelial compartments 
of GVHD target organs and destroying host tissues. Th1 CD4+ T cells mediate GVHD 
primarily through Fas/FasL mediated apoptosis, but also mediate epithelial damage via 
IL-1 and TNFα (Teshima et al., 2002). CD8+ T cells kill target tissues by direct contact to 
target cell or by release of cytotoxic soluble mediators (Ferrara et al., 1999). Contact 
dependent CD8+ T cell killing mechanisms include the Fas/FasL interaction and 
perforin/granzyme mediated cytotoxicity (Ferrara et al., 1999). In murine models where 
appropriate genetic differences exist, CD4+ T cells can induce GVHD by responding to 
MHC Class II differences; whereas, MHC Class I differences will elicit CD8+ T cell driven 
GVHD responses (Sprent et al., 1990). However, differences in miHAs elicit GVHD 
reactions from either CD4+ or CD8+ T cells following HLA-matched bone marrow 
transplantation. 
www.intechopen.com
The Use of Flow Cytometry to Monitor T Cell Responses  
in Experimental Models of Graft-Versus-Host Disease 
 
157 
3. Characterization of T cells during GVHD 
3.1 T cell phenotypes involved in GVHD 
Initially upon transfer from donor to host, donor T cells are in a naive state. Naive T cells 
characteristically express the lymphocyte homing receptor CD62L (L-selectin). The ligands 
for CD62L are GlyCAM-1, CD34, MadCAM-1, and PSGL-1. Each of these ligands are 
expressed on endothelial cells or high endothelial venules in the lymph node. Naive T cells 
home to host secondary lymphoid compartments following transplant. Naive T cells can be 
activated directly by antigen presentation by host APCs or indirectly by antigen 
presentation by donor APCs (Shlomchik et al., 1999; Teshima et al., 2002). Following 
activation, donor T cells down regulate CD62L, thereby freeing them from lymphoid 
recirculation, and upregulate integrins such as LFA-1 (CD11a/CD18) and VLA-4 
(CD49d/CD29) which enable extravasation into host tissues (Figure 1). Activated T cells also 
upregulate the C-Type lectin protein, CD69, and the high affinity alpha chain of the IL-2 
receptor (CD25).  
Effector memory T cells can be classified by their expression of the hyaluronic acid receptor, 
CD44. CD44 is expressed at low levels on naive cells, but is highly upregulated upon 
activation. Naive T cells can be isolated from donor mice and tested for the expression of 
naive or activation markers to predict the GVHD inducing potential of a given population of 
T cells. Furthermore, naive CD4+ T cells can be cultured to polarization to Th phenotype 
(Swain et al., 1991). Polarized CD4+ T cells can be transferred to irradiated recipients to 
induce GVHD (Fowler et al., 1996). 
It is well documented that adoptive transfer of naive T cells causes lethal GVD across either 
major or minor histocompatibility differences (OKunewick et al., 1990; Sprent et al., 1990); 
however, T cells of effector or memory phenotype are not as effective as naïve T cells in 
inducing GVHD following adoptive transfer into allogeneic recipients (Anderson et al., 
2003). Interestingly, central memory, effector memory, and effector CD8+ T cells have been 
shown to induce GVHD in a fully allogeneic strain combination (Zhang et al., 2005a); 
whereas, memory (characterized by the lack of CD62L expression) CD4+ T cells do not 
induce GVHD in either MHC-matched or MHC-disparate murine models (Anderson et al., 
2003; Chen et al., 2004). The mechanisms governing the lack of GVHD induction by memory 
CD4+ T cells remains unclear. However, it has been hypothesized by Sondel and colleagues 
that the T cells transferred by Anderson et al., were of the terminally differentiated, 
CD4+CD44hiCD62L-CD25- effector memory variety (Sondel et al., 2003). Effector memory 
differ from activated memory cells by their lack of CD69L and CD25 expression and lack the 
ability to home to central lymphoid tissue (Figure 1) (Sondel et al., 2003). The inability to 
home to lymphoid compartments following transfer in to host circulation presumably 
prevents donor T cells from being effectively primed against host antigens, thus leaving 
them unable to induce GVHD. The specificity that exists in choosing the appropriate cell 
type to induce GVHD provides an opportunity to utilize flow cytometry to aid in the 
induction of GVHD. Flow cytometry can be used to confirm or test the purity of a cultured 
cell population that has been induced into a certain phenotype. Flow cytometry can also 
identify the composition of donor splenocytes or lymph node cells. Historical data from 
Jackson Laboratories shows that the spleen of female B6 mice is comprised of roughly 16% 
CD4+ T cells and 10% CD8+ T cells (Jackson Laboratories). When testing hypotheses, it is of 
great importance to optimize experiments in order to obtain the most accurate results. Using 
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flow cytometry to understand the composition of a given cell population allows researchers 
to accurately perform and analyze experiments.  
 
Fig. 1. Naïve CD4+ T cells develop into effector or memory CD4+ T cells. When naïve CD4+ 
T cells (initially CD44-CD62L+CCR7+) are activated they either develop into central memory 
CD4+ T cells (CD44+CD62L+CD25-CCR7+) or effector CD4+ T cells (CD44+CD62L-CCR7-
CD25+CD49d+CD69+). Effector memory CD4+ T cells can extravasate into sites of 
inflammation or transition into central memory CD4+ T cells. Central memory CD4+ T cells 
can transition into effector memory CD4+ T cells (CCR1+CCR3+CCR5+CLA+CD103+VLA-
4+LFA-1+). Adapted from Sondel et al., 2003, JCI 
3.2 The role of regulatory T cells during GVHD 
Regulatory T cells (Tregs) are a population of T cells that have been shown to suppress 
GVHD in murine models (Johnson et al., 2002). Tregs are characterized and controlled by 
several phenotypic markers with the most universal being expression of the transcription 
factor forkhead box P3 (Foxp3) (Hori et al., 2003). Despite being the universal Treg 
regulator, Foxp3 is also transiently upregulated following activation of CD4+ T cells 
(Esposito et al., 2010). Because of this, the function of Foxp3 expressing cells can be 
ambiguous. Transient Foxp3 expression by recently activated Th1 CD4 T cells is 
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substantially lower than that in Foxp3 expressing Tregs (Esposito et al., 2010). Therefore, to 
accurately determine whether Foxp3 expression signifies a regulatory CD4+ T cell, protein 
quantification should be done. Protein quantification can be done through Western blotting 
and densitometry analysis. Moreover, CD25 is often used to classify CD4+ Tregs, but CD25 
is also expressed on recently activated Th1, Th2, or Th17 T cells as well. Therefore, 
confirmation of a flow cytometric determination of a cellular phenotype may be 
supplemented using alternative methods.  
CD4+ Tregs elicit several effector mechanisms, but they are widely regarded as 
immunosuppressive. Their immunosuppressive action can be carried out via cell-cell 
contact or secretion of anti-inflammatory cytokines including TGF┚ and IL-10. Tregs can be 
further characterized by surface expression of several other proteins, including the αE┚7 
integrin, CD103, which is broadly expressed by a variety of leukocyte subsets including 
activated CD8+ T cells, dendritic cells, and regulatory CD4+ and CD8+ T cells (Cepak et al., 
1994; Cerf-Bensussan et al. 1987; Huehn et al. 2004). CD103+ Tregs have been shown to have 
immunosuppressive properties reaching or exceeding those of their CD103- counterparts 
(Lehman et al., 2002). There is a population of CD25-CD103+ Tregs that express CTLA-4, 
suppress T cell proliferation in vitro, and prevent severe colitis in the SCID mouse (Lehmann 
et al., 2002). CD25-CD103+ Tregs also produce a distinct cytokine profile. This subset of 
Tregs typically produces IL-4, IL-5, and IL-13 to a similar extent as Th2 CD4+ T cells; 
however, this cytokine profile is largely absent in their CD25+ counterparts (Lehmann et al., 
2002).  
CD4+CD25+CD103+ Tregs exhibit immunosuppressive properties in vivo as well as in vitro. 
Chronic GVHD frequently occurs in patients that develop acute GVHD, and in vivo transfer 
of CD4+CD25+CD103+ Tregs in mice has been shown to suppress ongoing chronic GVHD, 
and has been shown to reduce the number of alloantibody producing plasma cells and 
pathogenic T cells in GVHD target organs (Zhao et al., 2008). CD103 is also present on the 
surface of a population of CD8+ Tregs. CD8+ Tregs can acquire their antigen specificity 
peripherally and promote systemic tolerance. Antigen specific CD8+ Tregs can be induced 
by antigen injection into the anterior chamber of the eye. CD103 has been shown to be 
essential for the development and function of the CD8+ Tregs (Keino et al., 2006). Koch et al. 
characterized CD103+CD8+ Tregs as phenotypically different from other CD8+ suppressor 
T cell populations. CD103+CD8+ Tregs express CD28, but lack Foxp3, CD25, LAG-3, CTLA-
4, and GITR (Koch et al., 2008). 
3.3 Cell specific depletion during GVHD 
Depletion of specific cell types can be an effective means to prevent GVHD. The most 
obvious clinical example of this is patients who receive T cell depleted grafts incur GVHD 
less frequently. However, this is not an effective treatment because globally depleting T cells 
results in increased rate of graft rejection, increased susceptibility to opportunistic infections, 
and increased rates of leukemic relapse. However, rare instances occur where the risk for 
severe GVHD is so great that the potential benefits outweigh the risks and T cells are 
selectively removed from the graft. In such instances, removal is done through the addition 
antibodies targeted to either CD4+ T cells, CD8+ T cells, or both. The antibodies are 
conjugated to magnetic beads and the graft-antibody mix is passed through a magnetic 
column. The magnetic beads bind to the magnetic column, so any CD4+ or CD8+ T cells  
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bound by antibody are retained in the column while the remainder of the graft passes 
through freely. Flow cytometry can be used to confirm the presence or absence of T cells. 
Flow cytometric analysis can be done not only on the T cell depleted graft to confirm the 
absence of the pan T cell marker, CD3, but analysis can be done on the cells retained in the 
column to confirm a pure population of T cells. Despite the dogma regarding T cells as the 
central mediators of GVHD pathology, researchers are now focusing their efforts on the role 
of B cells during GVHD. Rituximab is a monoclonal antibody directed to CD20, a pan 
mature B cell marker, and causes B cell depletion by antibody dependent cellular 
cytotoxicity (ADCC), complement dependent cytotoxicity (CDC), and direct arrest of 
cellular growth. Studies have shown an amelioration of chronic GVHD in patients who 
received Rituximab suggesting a prominent role for B cells in the progression of chronic 
GVHD (Alousi et al., 2010). 
4. Analyzing T cell responses during GVHD 
4.1 Isolating T cells 
To induce murine GVHD, T cells are infused via the tail vein and are immediately propelled 
into host circulation. Donor lymphocytes rapidly accumulate in host lymphoid tissue and 
expand within 2-3 days post transplant (Wysocki et al., 2005). At this point, donor 
lymphocytes can be isolated from either the secondary lymphoid tissue (spleen or lymph 
nodes) or peripheral blood. Peripheral blood is advantageous because it is not a terminal 
procedure; however, the lymphocyte yield is lower than that from the spleen or lymph 
nodes. Lymphocyte counts in the spleen of a naïve mouse can exceed 100 million cells. 
However, following lethal irradiation and GVHD induction, splenic lymphocyte counts may 
be limited to as low as 5 million total lymphocytes.  
Peripheral blood should be collected using a submandibular bleed. This can be done using a 
lancet to stick the submandibular vein just before it opens to the jugular vein (Golde et al., 
2005). The volume of blood collected should be less than 0.3 mL (Golde et al., 2005). 
Lymphocyte yield from peripheral blood will likely not exceed 1 million cells; however, 
yield will vary greatly with the strain combination used, disease state at which the blood 
was collected, and the volume of blood collected. Blood should be collected in a tube 
containing heparin (or any other anti-coagulation reagent) and the red blood cells should be 
lysed. Alternatively, the spleen can be removed following euthanization. The spleen should 
be minced and made into a single cell suspension and red blood cells should be lysed. Once 
the red blood cells are lysed, count the remaining lymphocytes and resuspend in FACS 
Buffer (10% FBS, 0.2% Sodium Azide in PBS).  
4.2 Setting up a flow cytometry experiment 
For each experiment that will be analyzed using flow cytometry, appropriate controls will 
need to be included. Those controls consist of a tube containing cells alone and a tube with 
each antibody alone. The cells alone control tube will allow the flow cytometer to calibrate 
the size and granularity of the cell population without antibody present. Additional tubes 
containing lymphocytes and each fluorochrome to be used in the experiment conjugated to 
an antibody that will positively bind the lymphocyte population (i.e. a positive control) 
should be added separately. The purpose of these tubes is to calibrate the cytometer to 
recognize each fluorochrome independently.  
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Lastly, isotype controls must be included and set up in individual tubes with lymphocytes. 
Isotypes are antibodies that are specific for an antigen that is not likely to be present on the 
cell population of interest. The isotype controls account for any non-specific binding of the 
antibodies of interest and can be helpful in accurately analyzing the data. If the experiment 
is designed to analyze cell populations of low frequency, it will be helpful to add each non-
isotype antibody in addition to adding the isotype control (see example). It is preferable to 
use the lymphocytes to be used in the experimental tubes for all of the control tubes; 
however, if this is logistically impossible, alternative lymphocytes can be used.  
For flow cytometry, incubate 1 million cells in separate test tubes that are compatible with 
the flow cytometer to be used with each antibody to be included in the experiment for 30 
minutes in the dark at 4 degrees Celsius. During this incubation period, incubate 
lymphocytes with each positive control tube and isotype controls. After the incubation 
period, wash off excess antibody with 3 mL of FACS Buffer and resuspend with 300 uL of a 
fixative solution such as FACS Fix Solution (FACS Buffer with 10% Neutral Buffered 
Formalin). The cells should be analyzed on a flow cytometer as soon as possible, but can be 
delayed for up to several days.  
Example Experiment: The goal in this example experiment is to identify the percent of naive 
CD8+ T cells in the spleen 7 days post transplant of 3 mice with GVHD. 
• Each mouse is to be euthanized and the spleens are to be removed. 
• Mince each spleen and create three single-celled suspensions by passing the spleen 
through a 40 uM nylon mesh filter. 
• Collect each suspension, pellet the cells and lyse the red blood cells. 
• Resuspend cells in FACS Buffer, count the cells, and transfer ~1 million cells (volume 
~100 uL) into 3 tubes. These tubes will contain the antibodies to analyze the percent of 
naive CD8+ T cells. 
• Combine all remaining cells and transfer ~1 million cells (volume ~100 uL) to 7 tubes. 
These tubes will make up the positive control and isotype tubes.  
• Because we want to know the frequency of naive CD8+ T cells, we will need to stain the 
cells with 3 different antibodies: 1) CD3e (to identify T cells), 2) CD8a (to identify the 
CD8 population of T cells), and 3) CD62L (To identify the naive population of CD8+ T 
cells. Because these are three relatively common antigens, they should be available on a 
variety of fluorochromes. For this example, we will use CD3e-FITC, CD8a-PE, CD62L-
APC. We will also need an isotype matched negative control for each antibody 
(Hamster IgG1-FITC, Rat IgG2a-PE, Rat IgG2a-APC respectively).  
• See Table 2 for detailed experimental set up. 
• Three mice were used (Tubes 5-7) so statistical analysis can be done to the flow 
cytometry data obtained.  
4.3 Analyzing T cells from the gut during intestinal GVHD 
During the conditioning regimen, the gut is heavily damaged and is a target organ of acute 
GVHD. Analyses of early T cell trafficking events indicate that T cells are primed against 
host antigens and migrate to the gut (Wysocki et al., 2005). The degree to which T cells are 
primed in the Peyer’s patches is a controversial matter; however, it is clear that secondary 
lymphoid tissue in the gut contributes to the perpetuation of donor T cell pathology (Murai  
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 FITC PE APC 
Tube 1 - - - 
Tube 2 CD4   
Tube 3  CD4  
Tube 4   CD4 
Tube 5 CD3e CD8a CD62L 
Tube 6 CD3e CD8a CD62L 
Tube 7 CD3e CD8a CD62L 
Tube 8 Isotype CD3 (Hamp. IgG1) CD8a CD62L 
Tube 9 CD3e Isotype CD8a (Rat IgG2a) CD62L 
Tube 10 CD3e CD8a Isotype CD62L (Rat IgG2a) 
Table 2. Sample of a table which describes the antibodies to be added to each tube 
et al., 2003; Welniak et al., 2006). We and others have modified the protocol Isolation of 
Mouse Small Intestine Intraepithelial Lymphocytes, Peyer’s Patch, and Lamina Propria Cells 
from the Current Protocols in Immunology series to isolate and analyze T cells that infiltrate 
the gut during GVHD. Briefly, the small intestine is removed and flushed with PBS. The 
Peyer’s Patches are removed and the small intestine is cut longitudinally and into ~5 mm 
sections. Intraepithelial lymphocytes (IELs) and, during GVHD, gut infiltrating lymphocytes 
(GILs) are isolated from the intestinal sections. 
Elegant flow cytometric experiments have been performed using GILs to test hypotheses 
regarding the role of T cell subsets during GVHD. El-Asady et al. used a competition based 
mixing experiment to show a role for CD103 in promoting CD8 T cell accumulation in the 
intestinal epithelium during GVHD. In this experiment, equal numbers of CD8+ T cells 
from CD90.1 (Thy1.1) congenic mice were mixed with CD8 T cells from a CD103-/- CD90.2 
(Thy1.2) mouse and transferred into irradiated recipients. At various time points, GILs 
were isolated an analyzed for the proportion of CD103-/- CD8+ T cells in the gut 
compared to the spleen. Their data show that the proportion of CD103-/- CD8+ T cells is 
lower at day 28 than in earlier time points. This indicates that CD103-/- CD8+ T cells are 
less efficient in their ability to accumulate in the gut during GVHD suggesting that CD103 
plays a significant role in promoting CD8+ T cell accumulation in the gut during GVHD 
(El-Asady et al., 2005). Furthermore, the T cell receptors on each set of CD8+ T cells is 
transgenic so that they only recognize an antigen expressed by host cells, thus adding a 
higher level of sophistication to the experiment and the conclusions that can be drawn 
from the results.  
1. 1B2 is the antibody that binds to the transgenic T cell receptor. 1B2 positive cells 
indicate they are of donor origin and are specific for host antigens. 
2. Thy1.1 (also known as CD90.1) positive cells represent the CD8 T cells that are able to 
express CD103. 
3. The proportion of Thy1.1 cells increases compared to Thy1.1 negative (Thy1.2/CD90.2) 
cells indicating that CD103 deficient cells are unable to effectively accumulate in the gut 
during GVHD. 
4. CD103-/- CD8 T cells are retained in the spleen with similar efficiency as wild type CD8 
T cells.  
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Fig. 2. CD103 promotes retention of CD8+ T cells in the gut during GVHD. Lethally 
irradiated BALB/c recipients were adoptively transferred with equal numbers (0.5x106) of 
donor (2C) CD103-/- (Thy1.2) or wild-type (Thy1.1) CD8+ T cells. Dot plots of 1B2 positive 
cells plotted against Thy1.1 positive cells show proportion of CD103-/- CD8+ T cells 
compared with wild-type CD8+ T cells at day 6, 12, 21, and 28. Adapted from El Asady et 
al., 2005, JEM 
4.4 The use of intracellular flow cytometry to monitor T cell responses during GVHD 
Intracellular staining for flow cytometry is a valuable technique for testing hypotheses 
regarding the function of various cell populations in that T cell function can be gleaned from 
the cytokines produced. To advance experiments in which surface markers are analyzed, 
cytokines can be probed for and analyzed via flow cytometry. Liu et al. exemplify the use of 
intracellular flow cytometry to help draw conclusions regarding the function of two T cell 
populations. In this study, intracellular flow cytometry was performed to compare the 
cytokine profile of wild type and CD103-/- CD8+ T cells. CD103-/- CD8+ T cells were 
shown to be equally effective in their ability to clear solid tumors as wild type CD8+ T cells 
following murine bone marrow transplantation. To confirm that CD103-/- CD8 T cells were 
mediating tumor clearance, those cells were isolated and the profile of cytokines produced 
queried (Liu et al., 2011). It was found that in fact CD103-/- CD8+ T cells produce the same 
levels of various proinflammatory cytokines as wild type CD8+ T cells. Coupling this 
finding with the finding that CD103-/- CD8 T cell recipients are able to clear tumor with 
similar efficacy as wild type CD8 T cell recipients leads to the logical conclusion that CD103-
/- CD8+ T cells are functionally similar with regard to tumor fighting ability as compared to 
wild type CD8+ T cells.  
4.5 Supplementing flow cytometry with bioluminescent imaging 
Bioluminescent imaging (BLI) is a technique that utilizes the light as a product of the 
chemical reaction between the enzyme luciferase and its substrate luciferin. Luciferase is a 
gene naturally expressed by fireflies and is responsible for their characteristic green glow. 
The luciferase gene has been inserted into the murine genome on the B6 background 
generating a mouse that constitutively expresses luciferase (Cao et al., 2005). T cell 
populations have been purified and transferred with luciferase negative cell populations for  
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induction of GVHD. Immediately following the administration of luciferin to GVHD 
recipients, recipients can be imaged in a charged coupled device (CCD) camera and a 
pseudo-colored image can be generated (Figure 3).  
The non-invasive nature of BLI allows its use to supplement data generated via flow 
cytometry. Determining the cell source for lymphocyte isolation and analysis by flow 
cytometry is driven by hypothesis testing and historical results. By utilizing BLI, researchers 
can determine the anatomical location of T cell accumulation in real time and can isolate T 
cells based on their accumulation patterns rather than being restricted to analyzing 
experimental animals at specific time points and specific compartments. 
  
Fig. 3. Bioluminescent imaging as a supplement to flow cytometry: Lethally irradiated BALB/c 
recipients were adoptively transferred with 107 wild-type splenocytes and 2x106 luciferase 
positive CD8+ T cells. A representative mouse is shown following 4 mg D-luciferin injection 
and imaging in Xenogen IVIS CCD camera for 5 minutes 
5. GHVD treatments 
5.1 Prophylactic treatment 
In the absence of GVHD prophylaxis, the incidence of acute GVHD is nearly 100% (Sullivan 
et al., 1986). Prophylactic treatment with methotrexate results in a substantial decrease in the 
incidence of acute GVHD (Storb et al., 1974). Methotrexate – originally used as a 
chemotherapeutic agent - acts to inhibit folic acid metabolism and the cellular result is the 
inability to synthesize DNA; thus, resulting in inhibition of cellular proliferation. Treatments 
with calcineurin inhibitors (cyclosporine and tacrolimus) are more efficacious in preventing 
GVHD. Calcineurin inhibitors act to block the action of the transcription factor nuclear 
factor of activated T cells (NFAT) (Crabtree, 1989; Shaw et al.,1988). Prophylactic use of  
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calcineurin inhibitors with low dose methotrexate results in as low as 20% GVHD incidence 
following bone marrow transplant (Nash et al., 1996; Storb et al., 1986). Flow cytometry can 
be used to monitor T cell responses following preventative treatment with methotrexate 
and/or calcineurin inhibitors. In murine models, carboxyfluorescein succinimidyl ester 
(CFSE) is used to monitor T cell proliferation by flow cytometry. CFSE is a fluorescent dye 
that is able to traverse cell membranes. CFSE is taken up by cells prior to adoptive transfer. 
As cells divide, CFSE is equally divided between daughter cells, so when cells are 
monitored by flow cytometry, cells that have gone through several rounds of divisions have 
markedly less CFSE than cells that have not proliferated.  
5.2 Treatment of established GVHD 
The primary treatment for established GVHD is the use of corticosteroids (Koreth & Antin, 
2008). Binding of corticosteroids to their receptors on immune cells causes the upregulation 
of anti-inflammatory transcription factors and a suppression of the immune system. 
Although corticosteroids are ineffective prophylactically, their use for treatment of ongoing 
GVHD is widely established and effective (Chao et al., 2000). Intracellular flow cytometry 
can be used to track the production of pro- or anti-inflammatory cytokines following 
corticosteroid treatment. Other treatments for establish GVHD include mycophenolate 
mofetil (MMF) and sirolimus (also called rapamycin), but have yet to supplant 
corticosteroids as the gold standard for treatment of established GVHD. Patients with 
disease progression after three days of corticosteroid treatment or patients that do not show 
improvement after seven days of corticosteroid treatment are considered to be steroid-
refractory and are treated with a more intense regimen. Such therapies include the use of 
monoclonal antibodies aimed to deplete T cell subsets. Monoclonal antibodies and/or 
fusion proteins can be used to block the action of proinflammatory cytokines. The efficacy of 
treatments for steroid-refractory GVHD is limited by lack of effectiveness or the high 
incidence of severe side effects. 
5.3 Prospective therapeutic approach 
Current prophylactic therapies of ongoing GVHD target a broad spectrum of cell types, and 
thus substantially inhibit post transplant immunity. Immunotherapies specifically targeted 
to GVHD-causing T cells are desirable. In mice, blockade of integrins expressed on T cells 
has been shown to be effective in preventing GVHD, while maintaining the beneficial 
properties of T cells post transplant (El-Asady et al., 2005; Liu et al., 2011). Waldman et al. 
has shown that the absence of the B7 integrin family on donor T cells results in reduced 
GVHD morbidity and mortality without compromising GVT effects (Waldman et al., 2006). 
Similarly, CD8+ T cells deficient in their ability to express CD103 are unable to induce 
GVHD, but maintain immunity to solid tumors (Lui et al., 2011). Flow cytometric sorting 
techniques can be used to selectively deplete T cells that express certain markers prior to 
transplantation. Cells are sorted based on fluorescence, so unbound cells are retained 
separately from cells bound by antibodies. This technique creates highly pure populations of 
cells of a given phenotype. Because proteins are expressed on T cell surfaces transiently and 
their expression is a dynamic process, cell sorting is limited to sorting cells based on their 
phenotype when analyzed. However, despite this limitation, the applications for flow 
cytometric sorting are vast due to the high throughput and accuracy with which cells are 
sorted.  
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Graft engineering is another therapeutic approach that has the potential to maintain post 
transplant immunity while preventing GVHD. Graft engineering is the idea of selectively 
depleting the mature donor T cell population of potentially pathogenic cells. The non-
pathogenic cells are retained in the graft and are able to promote engraftment, post-
transplant immunity, and GVT/GVL effects. Alternatively, T cells can be broadly depleted 
and repopulated with ex vivo expanded T cells that are specific for a particular tumor or 
microbial antigen. Several studies have demonstrated the ability to deplete alloreactive T 
cells or expand and adoptively transfer T cells specific for tumor (Verneris et al., 2001; 
Amrolia et al., 2004). Flow cytometry plays an important role in differentiating between 
tumor/pathogen reactive and alloreactive T cell populations. Because the sequences of 
many antigenic epitopes are known, synthetic peptides can be developed and conjugated to 
fluorochromes to be used for flow cytometry. T cells specific for the synthetic peptide bind 
their cognate antigen-fluorochrome complex and their frequency can be identified. 
Moreover, flow cytometric sorting techniques are able to remove these antigen-specific T 
cells from the graft. For ex vivo expansion of pathogen or tumor specific antigens, this 
application of flow cytometry is used to test the purity of the ex vivo expanded T cell 
population.  
To broadly suppress GVHD, Tregs can be expanded ex vivo and adoptively transferred into 
bone marrow transplant recipients. Until recently, adoptive transfer of Tregs was confined 
to murine models; however, in 2011, Tregs were expanded ex vivo and adoptively 
transferred into bone marrow transplant recipients (Brunstein et al., 2011). Suppression of 
the ex vivo expanded Treg population was confirmed in vitro and following adoptive 
transfer the incidence rate of acute GVHD was significantly lower in patients who received 
Tregs (Brunstein et al., 2011). In mice, several groups have reported that adoptive transfer of 
Tregs can reduce GVHD incidence and severity (Edinger et al., 2003; Taylor et al., 2002). 
Tregs act to reduce GVHD by inhibiting proinflammatory effector responses by donor T 
cells, but interestingly, addition of exogenous Tregs does not inhibit GVL effects in mice 
(Edinger et al., 2003).  
5.4 Concluding remarks 
Current prophylactic and first-line therapies for GVHD are limited due to the breadth of 
immune suppression. Global immunosuppressive approaches limit the beneficial properties 
of T cells post transplant. The use of engineered grafts is an exciting therapeutic approach as 
it has the potential to separate GVHD from the beneficial GVL effects. Adoptive transfer of 
ex vivo expanded Tregs also has the potential to separate GVHD from GVL and has been 
shown to ameliorate GVHD in bone marrow transplant recipients. Innovative advances in 
the ability to modify T cell subsets have opened the door to novel therapeutic approaches to 
preventing GVHD without attenuating GVL effects. 
In addition to facilitating the determination of efficacy of GVHD therapies, flow cytometry 
plays a central role in GVHD research. Flow cytometry aids researchers by allowing 
accurate identification of cellular phenotypes and cytokine profiles of cell populations 
involved in disease. GVHD remains the limiting factor to the broad use of bone marrow 
transplants as a curative therapy for hematological disorders. Flow cytometry is a valuable 
tool with a variety of applications to help separate GVHD from the beneficial properties of T 
cells post transplant.  
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